Limits...
Troponin and anti-troponin autoantibody levels in patients with ventricular noncompaction.

Erer HB, Güvenç TS, Kemik AS, Yılmaz HY, Kul Ş, Altay S, Sayar N, Kaya Y, Eren M - PLoS ONE (2013)

Bottom Line: Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups.Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit.Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG).

View Article: PubMed Central - PubMed

Affiliation: Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Research and Training Hospital, Department of Cardiology, İstanbul, Turkey.

ABSTRACT
Ventricular hypertrabeculation/noncompaction is a morphologic and functional anomaly of myocardium characterized by prominent trabeculae accompanied by deep recessus. Dilated cardiomyopathy with left ventricular failure is observed in these patients, while the cause or pathophysiologic nature of this complication is not known. Anti-troponin antibodies are formed against circulating cardiac troponins after an acute coronary event or conditions associated with chronic myocyte necrosis, such as dilated cardiomyopathy. In present study, we aimed to investigate cardiac troponins and anti troponin autoantibodies in ventricular noncompaction/hypertrabeculation patients with/without reduced ejection fraction. A total of 50 patients with ventricular noncompaction and 23 healthy volunteers were included in this study. Noncompaction/hypertrabeculation was diagnosed with two-dimensional echocardiography using appropriate criteria. Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups. Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit. Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG). Elevated cardiac troponins and anti-troponin I autoantibodies were observed in patients with noncompaction preceding the decline in systolic function and could indicate ongoing myocardial damage in these patients.

Show MeSH

Related in: MedlinePlus

Boxplot diagrams showing troponin I, anti-troponin I IgM, troponin T and antitroponin T IgM levels in study groups.Troponin I (A), antitroponin I IgM (B) and troponin T (C) measurements were elevated in both NC/HT groups compared to controls, while antitroponin T IgM (D) levels were only elevated in subgroup of patients with reduced ejection fraction.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585198&req=5

pone-0057648-g002: Boxplot diagrams showing troponin I, anti-troponin I IgM, troponin T and antitroponin T IgM levels in study groups.Troponin I (A), antitroponin I IgM (B) and troponin T (C) measurements were elevated in both NC/HT groups compared to controls, while antitroponin T IgM (D) levels were only elevated in subgroup of patients with reduced ejection fraction.

Mentions: Both troponin T and troponin I levels were significantly higher in both NC/HT groups (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group for troponin T; 28.98±9.21 ng/ml for NCNE group and 28.11±10.42 ng/ml for NCLE group for troponin I) compared to controls (13.42±4.19 pg/ml for troponin T, p<0.01 and 9.74±1.97 ng/ml for troponin I, p<0.001). Anti-troponin I IgM antibodies were significantly higher in NC/HT patients (1.92±0.43 µg/ml for NCNE group and 1.79±0.36 µg/ml for NCLE group) compared to healthy volunteers (0.80±0.23 µg/ml for controls, p<0.001). In contrast, anti-troponin T IgM levels are only elevated in patients with noncompaction and systolic dysfunction (15.81±6.52 µg/ml) compared to patients in NCNE group (12.33±5.68 µg/ml, p<0.05) and healthy controls (12.00±2.32 µg/ml, p<0.05). Anti-troponin T IgG levels were similar to that of IgM levels (11.91±2.33 µg/ml for healthy controls, 12.34±5.80 µg/ml for NCNE group and 16.46±6.25 µg/ml for NCLE group, p = 0.01) (Figure 2).


Troponin and anti-troponin autoantibody levels in patients with ventricular noncompaction.

Erer HB, Güvenç TS, Kemik AS, Yılmaz HY, Kul Ş, Altay S, Sayar N, Kaya Y, Eren M - PLoS ONE (2013)

Boxplot diagrams showing troponin I, anti-troponin I IgM, troponin T and antitroponin T IgM levels in study groups.Troponin I (A), antitroponin I IgM (B) and troponin T (C) measurements were elevated in both NC/HT groups compared to controls, while antitroponin T IgM (D) levels were only elevated in subgroup of patients with reduced ejection fraction.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585198&req=5

pone-0057648-g002: Boxplot diagrams showing troponin I, anti-troponin I IgM, troponin T and antitroponin T IgM levels in study groups.Troponin I (A), antitroponin I IgM (B) and troponin T (C) measurements were elevated in both NC/HT groups compared to controls, while antitroponin T IgM (D) levels were only elevated in subgroup of patients with reduced ejection fraction.
Mentions: Both troponin T and troponin I levels were significantly higher in both NC/HT groups (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group for troponin T; 28.98±9.21 ng/ml for NCNE group and 28.11±10.42 ng/ml for NCLE group for troponin I) compared to controls (13.42±4.19 pg/ml for troponin T, p<0.01 and 9.74±1.97 ng/ml for troponin I, p<0.001). Anti-troponin I IgM antibodies were significantly higher in NC/HT patients (1.92±0.43 µg/ml for NCNE group and 1.79±0.36 µg/ml for NCLE group) compared to healthy volunteers (0.80±0.23 µg/ml for controls, p<0.001). In contrast, anti-troponin T IgM levels are only elevated in patients with noncompaction and systolic dysfunction (15.81±6.52 µg/ml) compared to patients in NCNE group (12.33±5.68 µg/ml, p<0.05) and healthy controls (12.00±2.32 µg/ml, p<0.05). Anti-troponin T IgG levels were similar to that of IgM levels (11.91±2.33 µg/ml for healthy controls, 12.34±5.80 µg/ml for NCNE group and 16.46±6.25 µg/ml for NCLE group, p = 0.01) (Figure 2).

Bottom Line: Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups.Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit.Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG).

View Article: PubMed Central - PubMed

Affiliation: Dr. Siyami Ersek Cardiovascular and Thoracic Surgery Research and Training Hospital, Department of Cardiology, İstanbul, Turkey.

ABSTRACT
Ventricular hypertrabeculation/noncompaction is a morphologic and functional anomaly of myocardium characterized by prominent trabeculae accompanied by deep recessus. Dilated cardiomyopathy with left ventricular failure is observed in these patients, while the cause or pathophysiologic nature of this complication is not known. Anti-troponin antibodies are formed against circulating cardiac troponins after an acute coronary event or conditions associated with chronic myocyte necrosis, such as dilated cardiomyopathy. In present study, we aimed to investigate cardiac troponins and anti troponin autoantibodies in ventricular noncompaction/hypertrabeculation patients with/without reduced ejection fraction. A total of 50 patients with ventricular noncompaction and 23 healthy volunteers were included in this study. Noncompaction/hypertrabeculation was diagnosed with two-dimensional echocardiography using appropriate criteria. Depending on ejection fraction, patients were grouped into noncompaction with preserved EF (LVEF >50%, n = 24) and noncompaction with reduced EF (LVEF <35%, n = 26) groups. Troponin I, troponin T, anti-troponin I IgM and anti-troponin T IgM were measured with sandwich immunoassay method using a commercially available kit. Patients with noncompaction had significantly higher troponin I (28.98±9.21 ng/ml in NCNE group and 28.11±10.42 ng/ml in NCLE group), troponin T (22.17±6.97 pg/ml in NCNE group and 22.78±7.76 pg/ml in NCLE group) and antitroponin I IgM (1.92±0.43 µg/ml in NCNE group and 1.79±0.36 µg/ml in NCLE group) levels compared to control group, while antitroponin T IgM and IgG were only elevated in patients with noncompaction and reduced EF (15.81±6.52 µg/ml for IgM and 16.46±6.25 µg/ml for IgG). Elevated cardiac troponins and anti-troponin I autoantibodies were observed in patients with noncompaction preceding the decline in systolic function and could indicate ongoing myocardial damage in these patients.

Show MeSH
Related in: MedlinePlus